Pharma is paying a huge price by delaying on predictive maintenance
For decades, regulatory bodies like the FDA have created a culture of risk aversion. In response, pharma and medical product companies have designed maintenance programs that over-inspect and over-spend on equipment. Profit margins may allow for it, but there are significant downsides to this strategy, including safety risks, negative ESG impacts, avoidable costs, and low asset utilization.
To understand the full impact of delaying the evolution of predictive maintenance, we had Zach Gilula, Pharma Machine Health Lead at Augury and David Seignolle, former VP, Head of Operations at Teva, discussing how pharma and medical product companies can overcome their outdated cautiousness to:
Cut maintenance costs and deviation incidents
Reduce third-party dependencies
Gain greater control over your their manufacturing environments